Clinical trial
A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination with Pembrolizumab As a First-line Treatment for Subjects with PD-L1 Positive Advanced Non-Small Cell Lung Cancer
NCT04515979 is registered in ClinicalTrials.gov with MedPacto, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination with Pembrolizumab As a First-line Treatment for Subjects with PD-L1 Positive Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- MedPacto, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 17, 2020
- Completion date
- August 5, 2024
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.